E
Eliud Hernandez-O'Farrill
Researcher at University of Puerto Rico, Medical Sciences Campus
Publications - 7
Citations - 107
Eliud Hernandez-O'Farrill is an academic researcher from University of Puerto Rico, Medical Sciences Campus. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 3, co-authored 6 publications receiving 74 citations. Previous affiliations of Eliud Hernandez-O'Farrill include University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer
Tessa Humphries-Bickley,Linette Castillo-Pichardo,Linette Castillo-Pichardo,Eliud Hernandez-O'Farrill,Luis D. Borrero-Garcia,Ingrid Forestier-Roman,Yamil Gerena,Manuel Blanco,Michael John Rivera-Robles,José R. Rodríguez-Medina,Luis A. Cubano,Cornelis P. Vlaar,Suranganie Dharmawardhane +12 more
TL;DR: MBQ-167 is 10× more potent than other currently available Rac/Cdc42 inhibitors and has the potential to be developed as an anticancer drug, as well as a dual inhibitory probe for the study of Rac and Cdc42.
Journal ArticleDOI
Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry.
Tessa Humphries-Bickley,Linette Castillo-Pichardo,Francheska Corujo-Carro,Jorge Duconge,Eliud Hernandez-O'Farrill,Cornelis Vlaar,José F. Rodríguez-Orengo,Luis A. Cubano,Suranganie Dharmawardhane +8 more
TL;DR: The pharmacokinetics and bioavailability of EHop-016 at different dosages in a single dose input scheme (10, 20 and 40 mg/kg BW) following intraperitoneal (IP) and oral gavage (PO) administration to nude mice support further preclinical evaluation of E Hop-016 as a new anti-cancer therapy.
Journal ArticleDOI
Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography–Tandem Mass Spectrometry
Maria Del Mar Maldonado,Gabriela Rosado-González,Joseph Bloom,Jorge Duconge,Jean F. Ruiz-Calderon,Eliud Hernandez-O'Farrill,Cornelis P. Vlaar,José F. Rodríguez-Orengo,Suranganie Dharmawardhane +8 more
TL;DR: The pharmacokinetics and tissue distribution of MBQ-167 following intraperitoneal and oral single-dose administrations are reported and supports further preclinical evaluation of this drug as a potential anticancer therapeutic.
Journal ArticleDOI
Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors.
Ginette S Santiago-Sánchez,Ricardo A Noriega-Rivera,Eliud Hernandez-O'Farrill,Fatma Valiyeva,Blanca I Quiñones-Díaz,Emilly S. Villodre,Bisrat G. Debeb,Andrea Rosado-Albacarys,Pablo E. Vivas-Mejia +8 more
TL;DR: In this paper, the authors proposed Lipocalin-2 (LCN2)-a secreted glycoprotein aberrantly abundant in different cancers-as a plausible target for IBC.
Patent
1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
Cornelis P. Vlaar,Dharmawardhane Flanagan Suranganie,Eliud Hernandez-O'Farrill,Linette Castillo-Pichardo +3 more
TL;DR: In this paper, compounds that inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis have been disclosed for treatment of cancer and hyperproliferative diseases.